-

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

Setting new standards for intelligent mass detection, sensitivity, and sustainability

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories. These advanced, intelligent systems are particularly well-suited for analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins.

The Pro iQ Series is designed to serve a broad range of end markets, including pharmaceutical and biopharmaceutical industries, academic and government research institutions, environmental testing labs, food safety organizations, and the chemical and specialty materials sector. With its precision, sensitivity, and intelligent design, the series supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification—empowering scientists to achieve high-quality, reliable results in both routine and advanced analytical workflows.

Dr. Iris Mangelschots, vice president and general manager of Agilent’s Liquid Phase Division, emphasized the strategic significance of the launch:

“With the launch of the Pro iQ Series, Agilent is redefining the future of liquid chromatography detection and demonstrating our continuing commitment to delivering leading-edge solutions to help customers push the boundaries of scientific discovery. The advanced Pro iQ Series will empower researchers to achieve unprecedented levels of insight and efficiency, making complex analyses more accessible and sustainable.”

The Pro iQ Series delivers exceptional performance and sensitivity, making it ideal for monitoring complex biomolecules and detecting impurities. Whether analyzing therapeutic small molecules, oligonucleotides, peptides, or proteins, the systems provide robust, high-resolution data to ensure accuracy, safety, and stability. The series also enables mass-based purification, allowing precise isolation of target compounds for downstream applications.

The Pro iQ Plus system is engineered for high-end applications that demand ultimate sensitivity and performance. With an expanded mass range of m/z 2–3,000 and enhanced sensitivity through Agilent Jet Stream (AJS) technology, it supports both routine and trace-level detection of small and large molecules. These capabilities make it especially valuable in advanced R&D environments where extended analytical performance is critical.

Both the Pro iQ and Pro iQ Plus systems are designed for operational efficiency and ease of use, enabling faster compound confirmation with greater specificity and selectivity than traditional UV detection—even for chromatographically unresolved compounds. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, making it a reliable choice for standard laboratory workflows.

Jennifer Gushue, associate vice president of LC/MS Product Marketing at Agilent, highlighted the broad applicability of the new systems:

“The versatility of the Pro iQ Series opens new possibilities across a wide spectrum of application areas—from pharmaceutical development and quality control to biotherapeutics, environmental testing, and academic research. Whether it's ensuring the purity of life-saving drugs, characterizing complex biomolecules—such as oligonucleotides and peptides—or advancing cutting-edge research, these systems deliver the precision, sensitivity, and intelligence today’s scientists need to solve tomorrow’s challenges.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom